NDA 018896 · Hospira
Potassium Acetate
Potassium Acetate · Injection
Last checked: Nov 20, 2026Latest source record: Jun 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Jul 20, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
4 Phase 3, 0 recruiting
FAERS reports
1,458
1,056 serious, 160 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 27, 2026.
INDICATIONS AND USAGE Potassium Acetate Injection, USP (2 mEq/mL) is indicated as a source of potassium, for the addition to large volume intravenous fluids, to prevent or correct hypokalemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- POTASSIUM ACETATE · POTASSIUM ACETATE 2MEQ/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Potassium Acetate" as an intervention, any sponsor and status, largest first.
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in SepsisPivotal-lookingCompleted
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT04102371 · 9,041 participants · Start Aug 25, 2020 · Primary completion Dec 1, 2025
Drug: Lactated Ringer; Normal Saline and 1 more · For: Shock; Septic
Sites: Davis, California; Los Angeles, California; San Francisco, California · 22 sites in all
- Albumin in Cardiac SurgeryPivotal-lookingCompleted
Helsinki University Central HospitalAcademic, hospital or other
NCT02560519 · 1,386 participants · Start Mar 21, 2017 · Primary completion Apr 13, 2020
Drug: Albumin solution; Ringers acetate solution · For: C.Surgical Procedure; Cardiac
Sites: Helsinki, Finland
- Midodrine and Fludrocortisone for Vasovagal SyncopePivotal-lookingStatus unknown
Tehran Heart CenterAcademic, hospital or other
NCT04595942 · 1,375 participants (planned) · Start Nov 19, 2020 · Primary completion Oct 2023
Drug: Midodrine Hydrochloride Tablets; Fludrocortisone Acetate Tablets · For: Syncope, Vasovagal
Sites: Tehran, Iran
- Benefits of GIK in Cardiac Surgery PatientsPivotal-lookingStatus unknown
Xijing HospitalAcademic, hospital or other
NCT01516138 · 930 participants · Start Feb 2012 · Primary completion Mar 2013
Drug: GIK; Control · For: Cardiac Surgery; Cardiopulmonary Bypass
Sites: Xi'an, China
- Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic StrokePivotal-lookingNot yet recruiting
Capital Medical UniversityAcademic, hospital or other
NCT06374823 · 342 participants (planned) · Start May 2024 · Primary completion Dec 2026
Drug: Multiple Electrolyte; Normal Saline · For: Critical Care; Hyperchloremia; Hemorrhagic Stroke
Sites: Beijing, China
- Hypernatremia Fluid Therapy in Childhood DiarrhoeaPivotal-lookingEnrolling by invitation
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT07884747 · 268 participants (planned) · Start Jan 13, 2026 · Primary completion Dec 12, 2028
Drug: Oral rehydration solution (ORS) · For: Hypernatremia; Acute Watery Diarrhea
Sites: Dhaka, Bangladesh
- Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac SurgeryPivotal-lookingCompleted
Assiut UniversityAcademic, hospital or other
NCT06414330 · 124 participants · Start Jun 1, 2024 · Primary completion Nov 12, 2025
Drug: Ringer acetate based Del Nido cardioplegia; HTK · For: Cardiac Ischemia
Sites: Asyut, Egypt
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02157506 · 70 participants · Start Jun 30, 2014 · Primary completion May 31, 2015
Drug: CXL-1427; Placebo · For: Heart Failure; Decompensated Heart Failure; Acute Heart Failure
Sites: Gainesville, Florida; Jacksonville, Florida; Macon, Georgia · 35 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea109
- diarrhoea108
- nausea108
- fatigue103
- asthenia85
- dizziness84
- drug ineffective84
- headache61
- weight decreased60
- death57
- pain57
- vomiting57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 90 |
| 2006 | 242 |
| 2007 | 424 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 75 |
| 2012 | 96 |
| 2013 | 12 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 39 |
| 2017 | 31 |
| 2018 | 56 |
| 2019 | 62 |
| 2020 | 55 |
| 2021 | 34 |
| 2022 | 38 |
| 2023 | 26 |
| 2024 | 42 |
| 2025 | 34 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Potassium Acetate (Potassium Acetate)
2024 spending
$2K
Beneficiaries
n/a
48 claims
Per beneficiary
n/a
$0.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,383 |
| 2021 | $9,063 |
| 2022 | $734 |
| 2023 | $2,555 |
| 2024 | $2,499 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Correction of factitious hyperkalemia in hemolyzed specimens.
Owens H, Siparsky G, Bajaj L, et al. · Am J Emerg Med 2005 · Controlled Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.